Publications

Search for any of these articles on PubMed

Immunology Research Program investigators are indicated in bold; co-authors who are primary members of other NCCC Research Programs are indicated in bold italics.

Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT (2006). Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439(7076):599-603.

Agrawal YP, Freedman M, Szczepiorkowski ZM (2005). Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: A case report. Transfusion 45(11):1735-1738.

Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM (2004). Combined TLR and CD40 triggering induces potent CD8+ T Cell expansion with variable dependence on Type I IFN. J Exp Med 199(6):775-784.

*Amiel E, Nicholson-Dykstra S, Walters JJ, Higgs H, Berwin B (2007). Scavenger receptor-A functions in phagocytosis of E. coli by bone marrow dendritic cells. Exp Cell Res 313(7):1438-1448.

*Armand R, Channon JY, Kintner J, White KA, Miselis KA, Perez RP, Lewis LD (2004). The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells). Toxicol Appl Pharmacol 196(1):68-79.

Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM (2007). Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother (1997) 30(6):577-590.

Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Jr., Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L (2007). Innovations and challenges in renal cell carcinoma: Summary statement from the Second Cambridge Conference. Clin Cancer Res 13(2 Pt 2):667s-670s.

Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR, Berwin BL (2007). Scavenger receptor-a-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 67(10):4783-4789.

Barber A, Zhang T, Demars LR, Conejo-Garcia J, Roby KF, Sentman CL (2007). Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 67(10):5003-5008.

Barber MA, Zhang T, Gagne BA, Sentman CL (2007). NK Cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J Immunol 178(10):6140-6147.

Barber MA, Zhang T, Gagne BA, Van Ginderachter JA, De Baetselier P, Sentman CL (2007, In press). Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunol Immunother.

*Barth RJ, Jr., Gibson GR, Carney PA, Mott LA, Becher RD, Poplack SP (2005). Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy. AJR Am J Roentgenol 184(1):324-329.

Becher B, Durell BG, Noelle RJ (2003). IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clinic Invest 112(8):1186-1191.

Benatuil L, Kaye J, Rich RF, Fishman JA, Green WR, Iacomini J (2005). The influence of natural antibody specificity on antigen immunogenicity. Eur J Immunol 35(9):2638-2647.
Benencia F, Courreges MC, Conejo-Garcia JR, Buckanovich RJ, Zhang L, Carroll RH, Morgan MA, Coukos G (2005). Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 16(6):765-778.

Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N, Coukos G (2005). HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 12(5):789-802.

Benencia F, Courreges MC, Conejo-Garcia JR, Mohammed-Hadley A, Coukos G (2006). Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biol Ther 5(7):867-874.

Benson MJ, Erickson LD, Gleeson MW, Noelle RJ (2007). Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 19(3):275-280.

Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ (2007). All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 204(8):1765-1774.

Bercovici N, Givan AL, Waugh MG, Fisher JL, Vernel-Pauillac F, Ernstoff MS, Abastado JP, Wallace PK (2003). Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods 276(1-2):5-17.

Beriault V, Jean-Francois C, Levesque K, LeBel C, Yong X, Chabot B, Cohen EA, Cochrane AW, Rigby WF, Mouland AJ (2004). A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag and Vpr localization. J Biol Chem 279(42):44141-44153.

Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV (2004). SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem 279(49):51250-51257.

Best CA, Laposata M, Proios VG, Szczepiorkowski ZM (2006). Method to assess fatty acid ethyl ester binding to albumin. Alcohol Alcohol 41(3):240-246.

Brooks SA, Connolly JE, Rigby WF (2004). The role of mRNA turnover in the regulation of tristetraprolin expression: Evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J Immunol 172(12):7263-7271.

Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Conejo-Garcia JR, Benencia F, Liotta LA, Gimotty PA, Coukos G (2006). Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther 5(6):635-642.

Chalermskulrat W, McKinnon KP, Brickey WJ, Neuringer IP, Park RC, Sterka DG, Long BR, McNeillie P, Noelle RJ, Ting JP, Aris RM (2006). Combined donor specific transfusion and anti-CD154 therapy achieves airway allograft tolerance. Thorax 61(1):61-67.

Chamberlain MC, Glantz MJ, Fadul CE (2007). Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue. Neurology 69(10):969-973.

Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, Linowski GJ, Jaracz E (2005). Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 53(2 Suppl 2):S177-S185.

*Chapman MS, Spenncer SK, Brennick JB (2003). Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 14(5):943-944.

Cheng SX, Chapman MS, Margesson LJ, Birenbaum D (2004). Genital ulcers caused by Epstein-Barr virus. J Am Acad Dermatol 51(5):824-826.

Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA (2003). Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol 21(16):3133-3140.

Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN (2006). Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66(9):4904-4912.

Conejo-Garcia JR, Benencia F, Courreges MC, Gimotty PA, Khang E, Buckanovich RJ, Frauwirth KA, Zhang L, Katsaros D, Thompson CB, Levine B, Coukos G (2004). Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res 64(6):2175-2182.

Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10(9):950-958.

Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, Vinocur JM, Buckanovich RJ, Thompson CB, Levine B, Coukos G (2003). Letal, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther 2(4):446-451.

Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G (2005). Vascular leukocytes contribute to tumor vascularization. Blood 105(2):679-681.

Cook WJ, Green KA, Obar JJ, Green WR (2003). Quantitative analysis of LP-BM5 murine leukemia retrovirus RNA using real-time RT-PCR. J Virol Methods 108(1):49-58.

Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR (2005). The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 92(7):1182-1187.

Coukos G, Conejo-Garcia JR, Buckanovich R, Benencia F (2007). Vascular leukocytes: A population with angiogenic and immunosupressive properties highly represented in ovarian cancer. Adv Exp Med Biol 590:185-193.

Coukos G, Conejo-Garcia JR, Roden RB, Wu TC (2005). Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 5(9):1193-1210.

Courreges MC, Benencia F, Conejo-Garcia JR, Zhang L, Coukos G (2006). Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer Gene Ther 13(2):182-193.

*Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL, Ernstoff MS (2005). Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. Clin Immunol 117(1):6-11.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942-949.

Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, Bell S, Harcourt G, Walker BD, Klenerman P, Wucherpfennig KW (2003). Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 112(6):831-842.

Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ (2003). Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20(3):271-281.

Eichbaum QG, Dzik WH, Chung RT, Szczepiorkowski ZM (2005). Red blood cell exchange transfusion in two patients with advanced erythropoietic protoporphyria. Transfusion 45(2):208-213.

Erickson LD, Lin LL, Duan B, Morel L, Noelle RJ (2003). A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A 100(22):12905-12910.

Eriksson M, Meadows SK, Basu S, Mselle TF, Wira CR, Sentman CL (2006). TLRs mediate IFN-{gamma} production by human uterine NK cells in endometrium. J Immunol 176(10):6219-6224.

Eriksson M, Meadows SK, Wira CR, Sentman CL (2004). Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-{beta}. J Leukoc Biol 76(3):667-675.

Eriksson M, Meadows SK, Wira CR, Sentman CL (2006). Endogenous transforming growth factor-beta Inhibits toll-like receptor mediated activation of human uterine natural killer cells. Am J Reprod Immunol 56(5-6):321-328.

Ernstoff MS (2005). Self-recognition and tumor response to immunotherapy. J Clin Oncol 23(25):5875-5877.

*Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ, Jr., Heaney JA, Noelle RJ (2007). Developing a rational tumor vaccine therapy for renal cell carcinoma: Immune yin and yang. Clin Cancer Res 13(2 Pt 2):733s-740s.

Fabiola F, Chapman MS (2005). Fitting of high-resolution structures into electron microscopy reconstruction images. Structure (Camb) 13(3):389-400.

Fadul CE (2005). "Pain due to neoplasms of the head and neck." In: Levin M, Ward TN (ed). A Case-based Handbook of Diagnosis, Mangement, and Prognosis: Anadem, Columbus, OH, pp.

*Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE (2004). Pituitary carcinomas respond to temozolomide. Neuro-Oncology 6:374.

*Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006). Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621-626.

Fadul CE, Stommel EW, Dragnev KH, Eskey CJ, Dalmau JO (2005). Focal paraneoplastic limbic encephalitis presenting as orgasmic epilepsy. J Neurooncol 72(2):195-198.

Fadul CE, Zacharski LR (2005). Coagulation biology in glioma pathogenesis: A missing link? J Thromb Haemost 3(9):1915-1916.

Fahey JV, Schaefer TM, Channon JY, Wira CR (2005). Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod 20(6):1439-1446.

Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD (2006). Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 12(18):5511-5519.

Frleta D, Lin JT, Quezada SA, Wade TK, Barth RJ, Noelle RJ, Wade WF (2003). Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice. J Immunother 26(1):72-84.

Frleta D, Noelle RJ, Wade WF (2003). CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells. J Leukoc Biol 74:1064-1073.

Fuse S, Bellfy S, Yagita H, Usherwood EJ (2007). CD8+ T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand. J Immunol 178(8):5227-5236.

Fuse S, Obar JJ, Bellfy S, Leung EK, Zhang W, Usherwood EJ (2006). CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol 80(18):9159-9170.

Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Ukomadu C (2003). Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 36(12):1602-1605.

Gaur A, Green WR (2003). Analysis of the helper virus in murine retrovirus-induced immunodeficiency syndrome: Evidence for immunoselection of the dominant and subdominant CTL epitopes of the BM5 ecotropic virus. Viral Immunol 16(2):203-212.

Gaur A, Green WR (2005). Role of a cytotoxic-T-lymphocyte epitope-defined, alternative Gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome. J Virol 79(7):4308-4315.

Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ (2005). Cutting edge: Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174(4):1783-1786.

Gorham JD (2005). Transforming growth factor-beta1, Th1 responses, and autoimmune liver disease. Transfusion 45(2 Suppl):51S-59S.

Green KA, Ahonen CL, Cook WJ, Green WR (2004). CD40-associated TRAF 6 signaling is required for disease induction in a retrovirus-induced murine immunodeficiency. J Virol 78(11):6055-6060.

Green KA, Cook WJ, Sharpe AH, Green WR (2003). The CD154/CD40 interaction required for retrovirus-induced murine immunodeficiency syndrome is not mediated by upregulation of the CS80/CD86 costimulatory molecules. J Virol 76(24):13106-13110.

Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11(3):328-334.

Grundy M, Sentman CL (2005). GFP transgenic mice show dynamics of lung macrophages. Exp Cell Res 310(2):409-416.

Grundy MA, Sentman CL (2006). Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Exp Cell Res 312(19):3920-3926.

Grundy MA, Zhang T, Sentman CL (2007). NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunol Immunother 56(8):1153-1161.

Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN (2006). Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116(5):1382-1390.

Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH (2005). A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 202(2):231-237.

Hamilton BJ, Genin A, Cron RQ, Rigby WF (2003). Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression. Mol Cell Biol 23(2):510-525.

Haque A, Rachinel N, Quddus MR, Haque S, Kasper LH, Usherwood E (2004). Co-infection of malaria and gamma-herpesvirus: Exacerbated lung inflammation or cross-protection depends on the stage of viral infection. Clin Exp Immunol 138(3):396-404.

Ho O, Green WR (2006). Alternative translational products and cryptic T cell epitopes: Expecting the unexpected. J Immunol 177(12):8283-8289.

Ho O, Green WR (2006). Cytolytic CD8+ T cells directed against a cryptic epitope derived from a retroviral alternative reading frame confer disease protection. J Immunol 176(4):2470-2475.

Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ (2003). CD154 on the surface of CD4+CD25+ regulatory cells contributes to skin transplant tolerance. Transplant 76(9):1375-1379.

Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ (2007). Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 5(4):291-294.

Killoran TP, Wells WA, Barth RJ, Goodwin DW (2003). Leiomyosarcoma of the popliteal vein. Skeletal Radiol 32(3):174-178.

Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004). A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10(5):1670-1677.

Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007). Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38(1):185-189.

Krause A, Sillard R, Kleemeier B, Kluver E, Maronde E, Conejo-Garcia JR, Forssmann WG, Schulz-Knappe P, Nehls MC, Wattler F, Wattler S, Adermann K (2003). Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci 12(1):143-152.

Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A (2005). Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 141(9):1154.

Li W, Green WR (2006). The role of CD4 T cells in the pathogenesis of murine AIDS. J Virol 80(12):5777-5789.

Li W, Green WR (2007). Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed? Virology 360(1):58-71.

Lin JT, Kitzmiller TJ, Cates JM, Gorham JD (2005). MHC-independent genetic regulation of liver damage in a mouse model of autoimmune hepatocellular injury. Lab Invest 85(4):550-561.

Lin JT, Martin SL, Xia L, Gorham JD (2005). TGF-{beta}1 uses distinct mechanisms to Inhibit IFN-{gamma} expression in CD4+ T Cells at priming and at recall: Differential involvement of Stat4 and T-bet. J Immunol 174(10):5950-5958.

Lu LF, Ahonen CL, Lind EF, Raman VS, Cook WJ, Lin LL, Noelle RJ (2007). The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood 110(1):193-200.

Lu LF, Cook WJ, Lin LL, Noelle RJ (2003). CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem 278(46):45414-45418.

Lu LF, Gondek DC, Scott ZA, Noelle RJ (2005). NF{kappa}B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J Immunol 175(3):1651-1657.

Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ (2006). Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442(7106):997-1002.

Macrae AI, Usherwood EJ, Husain SM, Flano E, Kim IJ, Woodland DL, Nash AA, Blackman MA, Sample JT, Stewart JP (2003). Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis. J Virol 77(17):9700-9709.

Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B (2007). Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 13(11):3312-3319.

Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, Ward RL, Woodland DL, Lefrancois L (2004). Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 172(8):4875-4882.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB (2005). Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133-141.

Meadows SK, Eriksson M, Barber A, Sentman CL (2006). Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int Immunopharmacol 6(6):1020-1028.

Meehan KR, Fitzmaurice T, Root L, Kimtis E, Patchett L, Hill J (2006). The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol 4(4):187-190.

Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P, Szczepiorkowski ZM (2006). Implementation of peripheral blood CD34 analyses to initiate leukapheresis: Marked reduction in resource utilization. Transfusion 46(4):523-529.

Meehan KR, Tchekmedyian NS, Smith RE, Kallich J (2006). Resource utilization and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Investig 26(10):593-601.

Meehan KR, Wu J, Bengtson E, Hill J, Ely P, Szczepiorkowski Z, Kendall M, Ernstoff MS (2007). Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transplant 39(11):695-703.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE (2007).

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 25(15):2078-2085.

Mselle TF, Meadows SK, Eriksson M, Smith JM, Shen L, Wira CR, Sentman CL (2007). Unique characteristics of NK cells throughout the human female reproductive tract. Clin Immunol 124(1):69-76.

Noelle RJ, Erickson LD (2005). Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 8:1-24.

O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD (2003). The rise and fall of long-lived humoral immunity: Terminal differentiation of plasma cells in health and disease. Immunol Rev 194:61-76.

O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Ling-Li L, Mantchev GT, Bram RJ, Noelle RJ (2004). BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199(1):91-98.

O'Connor BP, Vogel LA, Zhang W, Loo W, Shnider D, Lind EF, Ratliff M, Noelle RJ, Erickson LD (2006). Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. J Immunol 177(11):7723-7732.

Obar JJ, Crist SG, Gondek DC, Usherwood EJ (2004). Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J Immunol 172(2):1213-1219.

Obar JJ, Crist SG, Leung EK, Usherwood EJ (2004). IL-15-independent proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus infection. J Immunol 173(4):2705-2714.

Obar JJ, Donovan DC, Crist SG, Silvia O, Stewart JP, Usherwood EJ (2004). T-cell responses to the m3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics. J Virol 78(19):10829-10832.

Obar JJ, Fuse S, Leung EK, Bellfy SC, Usherwood EJ (2006). Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol 80(17):8303-8315.

Ojeifo JO, Wu AG, Herscowitz HB, Meehan KR (2003). Phenotypic and immunologic characteristics of docetaxel-mobilized peripheral blood stem cells in mice. J Hematother Stem Cell Res 12(2):189-197.

Park IK, Letterio JJ, Gorham JD (2007). TGF-beta1 inhibition of IFN-gamma-induced signaling and Th1 gene expression in CD4(+) T cells is Smad3 independent but MAP kinase dependent. Mol Immunol 44(13):3283-3290.

Park IK, Shultz LD, Letterio JJ, Gorham JD (2005). TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4+ T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175(9):5666-5674.

Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338(2):284-293.

Parra Cid T, Conejo Garcia JR, Carballo Alvarez F, de Arriba G (2003). Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology 189(1-2):99-111.

Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS (2004). Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol Pharmacol 66(6):1406-1414.

Paulos CM, Turk MJ, Breur GJ, Low PS (2004). Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56(8):1205-1217.

*Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A (2006). Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 Inhibitor UCN-01 (NSC 638850). Clin Cancer Res 12(23):7079-7085.

*Pipas JM, Barth RJ, Jr., Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA (2005). Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12(12):995-1004.

*Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE (2005). A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71(3):301-305.

Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM (2003). Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 48(9):2541-2554.

Quezada SA, Fuller B, Jarvinen LZ, Gonzalez M, Blazar BR, Rudensky AY, Strom TB, Noelle RJ (2003). Mechanisms of donor-specific transfusion tolerance: Preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood 102(5):1920-1926.

Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ (2004). CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22:307-328.

Raman VS, Lind EF, Benson MJ, Noelle RJ (2007). Strategies for selective priming of memory B cells. Immunol Lett 109(2):93-100.

Randolph JJ, Wishart HA, Saykin AJ, McDonald BC, Schuschu KR, MacDonald JW, Mamourian AC, Fadul CE, Ryan KA, Kasper LH (2005). FLAIR lesion volume in multiple sclerosis: Relation to processing speed and verbal memory. J Int Neuropsychol Soc 11(2):205-209.

Rich RF, Cook WJ, Green WR (2006). Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral CTL. Virology 346(2):287-300.

Rich RF, Green WR (2006). Apoptosis of epitope-specific antiretroviral cytotoxic T lymphocytes via Fas ligand-Fas interactions. Viral Immunol 19(3):424-433.

Rigby WF (2005). Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications? Semin Arthritis Rheum 34(5 Pt 2):1-2.

Rigby WF (2007). Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 3(4):227-233.

Rigby WF, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, Brooks SA (2005). Structure/function analysis of Tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. J Immunol 174(12):7883-7893.

Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG (2006). Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 29(1):95-101.

Robinson RT, French MA, Kitzmiller TJ, Gorham JD (2006). Restriction of the CD4+ T-cell receptor repertoire prevents immune pathology in TGF-beta1 knockout mice. Lab Invest 86(8):815-828.

Robinson RT, Gorham JD (2004). Analysis of TCR Vbeta-usage by intrahepatic T helper cells in a mouse model of autoimmune hepatitis. Hepatology 40:420A.

Robinson RT, Gorham JD (2007). TGF-beta 1 regulates antigen-specific CD4+ T cell responses in the periphery. J Immunol 179(1):71-79.

Rodriguez-Jimenez FJ, Krause A, Schulz S, Forssmann WG, Conejo-Garcia JR, Schreeb R, Motzkus D (2003). Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics 81(2):175-183.

Rosser MF, Trotta BM, Marshall MR, Berwin B, Nicchitta CV (2004). Adenosine nucleotides and the regulation of GRP94-client protein interactions. Biochemistry 43(27):8835-8845.

Rudner LA, Lin JT, Park IK, Cates JM, Dyer DA, Franz DM, French MA, Duncan EM, White HD, Gorham JD (2003). Necroinflammatory liver disease in BALB/c background, TGF-beta 1-deficient mice requires CD4+ T cells. J Immunol 170(9):4785-4792.

Schalock PC, Kornik RI, Baughman RD, Chapman MS (2006). Treatment of verrucous carcinoma with topical imiquimod. J Am Acad Dermatol 54(5 Suppl):S233-S235.

*Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA, Ernstoff MS (2006). Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate 66(6):667-674.

*Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Wallen EM, Fisher JL, Waugh MG, Truman D, Stempkowski LM, Crosby NA, Heaney JA, Ernstoff MS (2004). Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol 171(3):1036-1042.

Scott SM, Szczepiorkowski ZM (2005). Rituximab for TTP. Am J Hematol 80(1):87-88.
Sentman CL, Barber MA, Barber A, Zhang T (2006). NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res 95:249-292.

Sentman CL, Meadows SK, Wira CR, Eriksson M (2004). Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol 173(11):6760-6766.

Sentman CL, Wira CR, Eriksson M (2007). NK cell function in the human female reproductive tract. Am J Reprod Immunol 57(2):108-115.

Sharp C, Thompson C, Samy ET, Noelle R, Tung KS (2003). CD40 ligand in pathogenesis of autoimmune ovarian disease of day 3-thymectomized mice: Implication for CD40 ligand antibody therapy. J Immunol 170(4):1667-1674.

Shaz BH, Linenberger ML, Bandarenko N, Winters JL, Kim HC, Marques MB, Sarode R, Schwartz J, Weinstein R, Wirk A, Szczepiorkowski ZM (2007). Category IV indications for therapeutic apheresis-ASFA fourth special issue. J Clin Apher 22:3.

Shen L, Smith JM, Shen Z, Eriksson M, Sentman C, Wira CR (2007). Inhibition of human neutrophil degranulation by transforming growth factor-beta1. Clin Exp Immunol 149(1):155-161.

Siegel A, Alvarado M, Barth RJ, Jr., Brady M, Lewis J (2006). Parameters in the prediction of the sensitivity of parathyroid scanning. Clin Nucl Med 31(11):679-682.

Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS (2007). Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 79(2):149-152.

Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ (2006). A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 107(6):1273-1279.

Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P (2004). MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. Embo J 23(6):1313-1324.

Sung JL, Lin JT, Gorham JD (2003). CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naive CD4+ T cells. Int Immunopharmacol 3(2):233-245.

Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006). Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552-553.

Szczepiorkowski ZM, AuBuchon JP (2006). The role of physicians in hospital transfusion services. Transfusion 46(5):862-867.

Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL (2007). Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 22(3):106-175.

Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL (2007). The new approach to assignment of ASFA categories-Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. J Clin Apher 22(3):96-105.

Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM (2006). Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 24(34):5408-5413.

Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR (2004). Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells downregulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 105(8):3372-3380.

*Titus-Ernstoff L, Ding J, Perry AE, Spenncer SK, Cole BF, Ernstoff MS (2007). Factors associated with atypical moles in New Hampshire, USA. Acta Derm Venereol 87(1):43-48.

*Titus-Ernstoff L, Perry AE, Spenncer SK, Gibson J, Ding J, Cole B, Ernstoff MS (2006). Multiple primary melanoma: Two-year results from a population-based study. Arch Dermatol 142(4):433-438.

*Titus-Ernstoff L, Perry AE, Spenncer SK, Gibson JJ, Cole BF, Ernstoff MS (2005). Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer 116:144-149.

*Tretter CP, Lewis LD, Fisher J, Waugh MG, Ernstoff MS (2003). Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J Chemother 15(5):472-479.

Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN (2004). Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200(6):771-782.

Turk MJ, Waters DJ, Low PS (2004). Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 213(2):165-172.

Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN (2006). Unraveling the complex relationship between cancer immunity and autoimmunity: Lessons from melanoma and vitiligo. Adv Immunol 90:215-241.

Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL (2005). Control of murine gammaherpesvirus infection is independent of NK cells. Eur J Immunol 35(10):2956-2961.

Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG (2006). Cutting edge: Dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol 176(12):7165-7169.

Waller EK, Ernstoff MS (2003). Modulation of antitumor immune responses by hematopoietic cytokines. Cancer 97(7):1797-1809.

Walters JJ, Berwin B (2005). Differential CD91 dependence for calreticulin and pseudomonas exotoxin-A endocytosis. Traffic 6(12):1173-1182.

Wells GL, Brown J, Manganiello WD, Chapman MS (2006). Tacrolimus ointment 0.1% for the treatment of peristomal skin disease: 3 case reports. Cutis 78(4):258-260.

Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L (2005). Innate and adaptive immunity in female genital tract: Cellular responses and interactions. Immunol Rev 206:306-335.

Wishart HA, Roberts DW, Roth RM, McDonald BC, Coffey DJ, Mamourian AC, Hartley C, Flashman LA, Fadul CE, Saykin AJ (2003). Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: Review and case report. J Neurol Neurosurg Psychiatry 74(10):1392-1397.

Wishart HA, Saykin AJ, McDonald BC, Mamourian AC, Flashman LA, Schuschu KR, Ryan KA, Fadul CE, Kasper LH (2004). Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology 62(2):234-238.

Wolniak KL, Noelle RJ, Waldschmidt TJ (2006). Characterization of (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific germinal center B cells and antigen-binding B220- cells after primary NP challenge in mice. J Immunol 177(4):2072-2079.

*Wu JY, Ernstoff MS, Hill JM, Cole B, Meehan KR (2006). Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy 8(2):141-148.

*Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, Perry A, Rhodes CH (2007). Atypical teratoid/rhabdoid tumor of the spine in an adult: Case report and review of the literature. J Neurooncol 84(1):49-55.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213.

Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G (2003). Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 9(1):264-272.

Zhang P, Cote AL, de Vries VC, Usherwood EJ, Turk MJ (2007). Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 67(13):6468-6476.

Zhang T, Barber A, Sentman CL (2006). Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 66(11):5927-5933.

Zhang T, Lemoi BA, Sentman CL (2005). Chimeric NK receptor-bearing T cells mediate anti-tumor immunotherapy. Blood 35(10):2956-2961.